Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 12;15:281–294. doi: 10.2147/CEOR.S404175

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Niazi.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Comparison of market share as a percentage of units contributed by biosimilars with the discount from the price of the reference product in 24 European countries and the US. European data [https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-Europe-2021.pdf]. US data [Barclay Global Pharmaceuticals; US Specialty Pharma. September 2022.] The US data are based on filgrastim, pegfilgrastim, trastuzumab, infliximab, and bevacizumab products till the third quarter of 2022.